Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532721 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL17768626 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL379328 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL15267245 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL30666992 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL12583743 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL16420396 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL18807211 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL1424574 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL15267240 | 0.74 | HTR2B (0.37) | HTR2AHTR2CHTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009118384-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | HTR2A 4125/4885HTR2C 4105/4885HTR2B 3040/4885 |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | HTR2A 1515/4885HTR2C 2169/4885HTR2B 1959/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | HTR2A 1515/4885HTR2C 2169/4885HTR2B 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.